• OPEN AN ACCOUNT
A+| A| A-|
Indian Indices
Sensex
76,664.21 -999.79
( -1.29%)
Global Indices
Nasdaq
49,249.13 -82.20
(-0.17%)
Dow Jones
7,185.72 56.32
(0.79%)
Hang Seng
59,744.07 603.84
(1.02%)
Nikkei 225
10,387.94 -69.07
(-0.66%)
Forex
USD-INR
94.05 0.29
(0.31%)
EUR-INR
109.99 0.01
(0.01%)
GBP-INR
126.84 0.17
(0.14%)
JPY-INR
0.59 0.00
(0.16%)

EQUITY - MARKET SCREENER

Tacent Projects Ltd
Industry :  Trading
BSE Code
ISIN Demat
Book Value()
531887
INE149D01011
-0.8102564
NSE Symbol
P/E(TTM)
Mar.Cap( Cr.)
N.A
0
14.9
EPS(TTM)
Face Value()
Div & Yield %
0
10
0
 

kotia enterprises ltd
Marksans Pharma’s arm gets USFDA approval for Loperamide Hydrochloride 2mg tablets
Nov 19,2025

The approved product is bioequivalent to the reference listed drug (RLD), Imodium A-D Tablets, 2 mg, marketed by Kenvue Brands LLC (NDA - 019860).

Loperamide Hydrochloride is an anti-diarrheal medication used to manage symptoms of acute and chronic diarrhea, strengthening Marksans Pharma’s portfolio in the US generic pharmaceutical market.

Marksans Pharma is primarily engaged in the business of research, manufacture, marketing and sale of pharmaceutical formulations.

The company’s consolidated net profit rose 1.6% to Rs 98.25 crore on 12.2% jump in revenue from operations to Rs 720.41 crore in Q2 FY26 over Q2 FY25.

Shares of Marksans Pharma fell 1.46% to Rs 189.50 on the BSE.